Iterum Therapeutics PLC expected to post a loss of 6 cents a share - Earnings Preview

Iterum Therapeutics

11/08/2021 13:47

* Iterum Therapeutics PLC  ITRM.OQ   ITRM.O  is expected to show
a no change in quarterly revenue when it reports results on
August 13. 
​* Refinitiv's mean analyst estimate for Iterum Therapeutics PLC
is for a loss of 6 cents per share. For the same quarter last
year, the company reported a loss of 80 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Iterum
Therapeutics PLC is $2.25​, about 68.3% above​ its last closing
price of $0.71. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.07       -0.07      -0.81     Missed  -1,057
                                                        .1
 Dec. 31 2020  -0.19       -0.19      -0.27     Missed  -39.7
 Sep. 30 2020  -0.51       -0.51      -0.60     Missed  -16.9​
 Jun. 30 2020  -0.67       -0.81      -0.80     Beat    1.2
 Mar.          -1.34​      -1.34      -0.90     Beat    32.7​
 31​ 2020​                                              
 Dec. 31 2019  -1.83       -1.70      -1.59     Beat    6.6​
 Sep. 30 2019  -1.71       -1.65      -2.15     Missed  -30.5
 Jun. 30 2019  -1.54       -1.53      -1.93     Missed  -26.1
 This summary was machine generated August 11 at 12:47 GMT.  All
figures in US dollars unless otherwise stated